Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label denosumab study in giant cell tumor of bone
NL-OMON47038Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Primary endpoint: Safety profile of denosumab. Started Mar 2009; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NL-OMON47038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47038.